Anti-Cancer Natural 98% Cabazitaxel
Product name
|
Cabazitaxel
|
Appearance
|
White Powder
|
CAS #
|
183133-96-2
|
Purity
|
98%
|
M.F.
|
C45H57NO14
|
Total Heavy Metals
|
≤10ppm
|
Loss on Drying
|
≤ 5%
|
Mesh size
|
95% pass 80 mesh
|
Sheliflife
|
2 Years
|
Cabazitaxel was developed by Sanofi-Aventis as an intravenous injectable drug for the treatment of hormone-refractory metastatic prostate cancer. As a microtubule inhibitor, cabazitaxel exhibits a much weaker affinity for P-glycoprotein (P-gp), an adenosine triphosphate (ATP)-dependent drug efflux pump. Cancer cells that express P-gp become resistant to taxanes. Clinical studies confirmed that cabazitaxel retains activity . Common adverse events with cabazitaxel include diarrhea and neutropenia. Cabazitaxel in combination with predni sone is an important new treatment option for men with metastatic CRPC (castration-resistant prostate cancer)
Function:
Cabazitaxel is a semisynthetic taxane derivative that acts as a microtubule inhibitor. It binds to tubulin, promoting the assembly of tubulin into microtubules and inhibiting their disassembly, which results in microtubule stabilization, the inhibition of cell division, cell cycle arrest and the arrest of tumour proliferation.
Application:
1.Cabazitaxel anticancer mechanism and characteristics, belongs to anti-microtubule drugs.
2.Cabazitaxel through binding to tubulin, promoting their assembly into microtubules.
3.It can prevent these have assembled a microtubule disintegration of the stabilization of microtubules, thereby inhibiting cell mitosis, and interphase cellular functions (interphasecellularfunctions) of play.
For Solid Product
|
For Liquid Product
|
|
|
Weight Range
|
Transportation Method
|
0.1~50 kg
|
Fedex, DHL, UPS, TNT, EMS
|
20~500 kg
|
By Air
|
> 500 kg
|
By Sea
|